Global reported endophthalmitis risk following intravitreal injections of anti-VEGF: A literature review and analysis

Keyphrases

• Intravitreal Injection 100%
• Endophthalmitis 100%
• Anti-vascular Endothelial Growth Factor (anti-VEGF) 100%
• Bevacizumab 57%
• Ranibizumab 57%
• Post-injection Endophthalmitis 28%
• High Risk 14%
• English Language 14%
• MEDLINE 14%
• Operating Room 14%
• Agent-based 14%
• Povidone-iodine (PVP-I) 14%
• Antibiotic Use 14%
• Causative Organisms 14%
• Associated Risk Factors 14%
• Avastin 14%
• Intravitreal Ranibizumab 14%
• Perioperative Factors 14%
• Topical Antibiotics 14%
• Anti-VEGF Therapy 14%
• Positive Risk 14%
• Lucentis 14%
• Streptococcus Spp 14%
• Eyelid Speculum 14%
• Occurrence Risk 14%
• Drug Compounding 14%

Medicine and Dentistry

• Intravitreal Administration 100%
• Endophthalmitis 100%
• Vasculotropin A 100%
• Bevacizumab 66%
• Ranibizumab 55%
• English (Language) 11%
• Antibiotics 11%
• Vasculotropin 11%
• Operating Room 11%
• Lid 11%
• Povidone Iodine 11%
• Streptococcus 11%

Pharmacology, Toxicology and Pharmaceutical Science

• Endophthalmitis 100%
• Intravitreal Administration 100%
• Vasculotropin A 100%
• Bevacizumab 66%
• Ranibizumab 55%
• Antibiotics 11%
• Vasculotropin 11%
• Streptococcus 11%
• Compounding 11%
• Povidone-Iodine 11%